EUVIMEDEUVIMED entdecken
Open Access

LAG3+ CD8+ T cell subset drives HR+/HER2− breast cancer reduction in bispecific antibody armed activated T cell therapy

Robert Weldon Barnes iD, Archana Thakur iD, Suna Onengut-Gumuscu iD, Lawrence G Lum iD, Sepideh Dolatshahi iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Robert Weldon Barnes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Virginia School of Medicine, Charlottesville, VA, United States. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Breast Neoplasms, CD8-Positive T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Genome Analysis and Technology Core, Biorepository and Tissue Research Facility, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor clearance by T cells is impaired by insufficient tumor antigen recognition, insufficient tumor infiltration, and the immunosuppressive tumor microenvironment. Although targeted T cell therapy circumvents failures in tumor antigen recognition, suppression by the tumor microenvironment and failure to infiltrate the tumor can hinder tumor clearance. Checkpoint inhibitors (CPIs) promise to reverse T cell suppression and can be combined with bispecific antibody armed T cell (BAT) therapy to improve clinical outcomes. We hypothesize that adoptively transferred T cell function may be improved by the addition of CPIs if the inhibitory pathway is functionally active. This study develops a kinetic-dynamic model of killing of hormone receptor–positive breast cancer cells mediated by BATs using single-cell transcriptomic and temporal protein data to identify T cell phenotypes and quantify inhibitory receptor expression. LAG3, PD-1, and TIGIT were identified as inhibitory receptors expressed by cytotoxic effector CD8 BATs upon exposure to hormone receptor–positive breast cancer cell lines. These data were combined with real-time tumor cytotoxicity data in a multivariate statistical analysis framework to predict the relevant contributions of T cells expressing each receptor to tumor reduction. A mechanistic kinetic-dynamic mathematical model was developed and parametrized using protein expression and cytotoxicity data for in silico validation of the findings of the multivariate statistical analysis. The model corroborated the predictions of the multivariate statistical analysis which identified LAG3+ BATs as the primary effectors, while TIGIT expression dampened cytotoxic function. These results inform CPI selection for BATs combination therapy and provide a framework to maximize BATs antitumor function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificBreast NeoplasmsCD8-Positive T-LymphocytesImmunotherapy, AdoptiveAntigens, CDT-Lymphocyte SubsetsHumansFemaleLymphocyte Activation Gene 3 ProteinTumor MicroenvironmentErb-b2 Receptor Tyrosine KinasesCell Line, TumorImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorReceptors, Immunologic

Stichwörter der Autor:innen

HR+/HER2−LAG3TIGITbispecific antibody armed T cellbreast cancercheckpoint inhibitorsmechanistic modelingrational design of combination therapiessystems immunologytherapeutic synergy

Substanzen

Antibodies, BispecificLymphocyte Activation Gene 3 ProteinErb-b2 Receptor Tyrosine KinasesAntigens, CDImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorReceptors, ImmunologicERBB2 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Virginia School of Medicine, Charlottesville, VA, United States.
  • University of Virginia Comprehensive Cancer Center, Charlottesville, VA, United States.
  • Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States.
  • Department of Genome Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States.
  • Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, VA, United States.

ORCID-Profile: Robert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu, Lawrence G Lum, Sepideh Dolatshahi

Förderung

  • Genome Analysis and Technology Core
  • Biorepository and Tissue Research Facility
  • NCI NIH HHS
  • NIGMS NIH HHS
  • UVA Comprehensive Cancer Center
  • NIAID NIH HHS
  • UVA Comprehensive Cancer
  • University of Virginia

Zitieren

APA

Barnes, R. W., Thakur, A., Onengut-Gumuscu, S., Lum, L. G., & Dolatshahi, S. (2025). LAG3+ CD8+ T cell subset drives HR+/HER2− breast cancer reduction in bispecific antibody armed activated T cell therapy. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf155

Vancouver

Barnes RW, Thakur A, Onengut-Gumuscu S, Lum LG, Dolatshahi S. LAG3+ CD8+ T cell subset drives HR+/HER2− breast cancer reduction in bispecific antibody armed activated T cell therapy. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf155

BibTeX
@article{Barnes2025,
  author = {Barnes, Robert Weldon and Thakur, Archana and Onengut-Gumuscu, Suna and Lum, Lawrence G and Dolatshahi, Sepideh},
  title = {LAG3+ CD8+ T cell subset drives HR+/HER2− breast cancer reduction in bispecific antibody armed activated T cell therapy},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf155}
}
Kostenlos starten →